Literature DB >> 9036925

Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts.

K Kikuchi1, T Kadono, M Furue, K Tamaki.   

Abstract

In scleroderma (systemic sclerosis, SSc), an autoimmune disorder in which excessive extracellular matrix is deposited in skin and internal organs, one of the suggested contributory factors to the development of fibrosis is a decrease in collagenase activity that may be related to levels of serum tissue inhibitors of metalloproteinases 1 (TIMP-1). We recently reported that the serum TIMP-1 levels in SSc patients were elevated compared with normal controls. To determine the biologic significance of TIMP-1 in SSc, we compared the proliferative effects of TIMP-1 between normal and SSc fibroblasts. TIMP-1 showed significant mitogenic activity for both normal and SSc fibroblasts. The mitogenic responses to TIMP-1 (33-100 ng/ml) in SSc fibroblasts, however, were significantly greater than those in normal controls and were completely neutralized in the presence of anti-TIMP-1 IgG. Moreover, anti-TIMP-1 IgG partially but significantly blocked the basal mitogenic activities of SSc fibroblasts. SSc fibroblasts produced increased amounts of TIMP-1 relative to normal fibroblasts, as confirmed by western blotting, ELISA, and RT-PCR techniques. In contrast, transforming growth factor beta1 (TGF-beta1) upregulated TIMP-1 production in normal fibroblasts but not in SSc fibroblasts with elevated spontaneous secretion of TIMP-1. These observations suggest that TIMP-1 may play an important role as an autocrine growth factor in the fibrotic process in SSc.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9036925     DOI: 10.1111/1523-1747.ep12286457

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  13 in total

1.  Analysis of TIMP-1 gene polymorphisms in Italian sclerodermic patients.

Authors:  Manuela Indelicato; Valentina Chiarenza; Massimo Libra; Grazia Malaponte; Valentina Bevelacqua; Maurizio Marchini; James A McCubrey; Franca Stivala; Raffaella Scorza; Maria Clorinda Mazzarino
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

2.  Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent.

Authors:  Narasimharao Bhagavathula; Marissa DaSilva; Muhammad N Aslam; Michael K Dame; Roscoe L Warner; Yiru Xu; Gary J Fisher; Kent J Johnson; Richard Swartz; James Varani
Journal:  Invest Radiol       Date:  2009-08       Impact factor: 6.016

3.  Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.

Authors:  S A Young-Min; C Beeton; R Laughton; T Plumpton; S Bartram; G Murphy; C Black; T E Cawston
Journal:  Ann Rheum Dis       Date:  2001-09       Impact factor: 19.103

4.  Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis.

Authors:  C Nishijima; I Hayakawa; T Matsushita; K Komura; M Hasegawa; K Takehara; S Sato
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

Review 5.  Redox-control of matrix metalloproteinase-1: a critical link between free radicals, matrix remodeling and degenerative disease.

Authors:  Supriya Kar; Sita Subbaram; Pauline M Carrico; J Andrés Melendez
Journal:  Respir Physiol Neurobiol       Date:  2010-09-08       Impact factor: 1.931

6.  Increased levels of serum tissue inhibitor of metalloproteinase-1 but not metalloproteinase-3 in atopic dermatitis.

Authors:  N Katoh; S Hirano; M Suehiro; K Ikenaga; H Yasuno
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

7.  The effect of TIMP-1 on the cone mosaic in the retina of the rat model of retinitis pigmentosa.

Authors:  Yerina Ji; Wan-Qing Yu; Yun Sung Eom; Farouk Bruce; Cheryl Mae Craft; Norberto M Grzywacz; Eun-Jin Lee
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-16       Impact factor: 4.799

8.  Expression of MMP-9 and TIMP-1 in lesions of systemic sclerosis and its implications.

Authors:  Chi Meng; Xu'e Chen; Jiawen Li; Yan Wu; Houjun Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-08-15

9.  Serum levels of tissue inhibitors of metalloproteinase 2 in patients with systemic sclerosis with duration more than 2 years: correlation with cardiac and pulmonary abnormalities.

Authors:  Amira Shahin; Amani Elsawaf; Shahira Ramadan; Olfat Shaker; Mona Amin; Mohamed Taha
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

10.  Elevated matrix metalloproteinase-9 in patients with systemic sclerosis.

Authors:  Wan-Uk Kim; So-Youn Min; Mi-La Cho; Kyung-Hee Hong; Yong-Joo Shin; Sung-Hwan Park; Chul-Soo Cho
Journal:  Arthritis Res Ther       Date:  2004-11-10       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.